Assessing Cardiac Amyloidosis Subtypes by Unsupervised Phenotype Clustering Analysis.

[1]  C. Rapezzi,et al.  Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner , 2020, BMC Family Practice.

[2]  A. Dispenzieri,et al.  Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. , 2020, JAMA.

[3]  M. Maurer,et al.  DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis , 2020, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[4]  C. Rapezzi,et al.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.

[5]  J. Butler,et al.  Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[6]  M. Hanna,et al.  Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis. , 2019, The Journal of hand surgery.

[7]  R. Falk,et al.  Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. , 2019, JACC. Heart failure.

[8]  É. Béquignon,et al.  Pharyngo-laryngeal involvement in systemic amyloidosis with cardiac involvement: a prospective observational study , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[9]  C. Rapezzi,et al.  Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS) , 2019, European heart journal.

[10]  D. Phelan,et al.  Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. , 2018, Journal of the American College of Cardiology.

[11]  Song Gao,et al.  Numero: a statistical framework to define multivariable subgroups in complex population-based datasets. , 2018, International journal of epidemiology.

[12]  V. Aboyans,et al.  Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis , 2017, Clinical Research in Cardiology.

[13]  É. Béquignon,et al.  How your ears can tell what is hidden in your heart: wild-type transthyretin amyloidosis as potential cause of sensorineural hearing loss inelderly-AmyloDEAFNESS pilot study , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[14]  J. Deux,et al.  Identification of prognostic markers in transthyretin and AL cardiac amyloidosis* , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[15]  A. Hagège,et al.  Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. , 2016, European heart journal.

[16]  C. Rapezzi,et al.  Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy , 2016, Open Heart.

[17]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[18]  F. Rutten,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[19]  B. Khandheria,et al.  The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. , 2014, European heart journal cardiovascular Imaging.

[20]  Glenn Fung,et al.  Personalized cardiovascular medicine: concepts and methodological considerations , 2013, Nature Reviews Cardiology.

[21]  Aman Sharma,et al.  Skin Involvement in Primary Systemic Amyloidosis , 2013, Mediterranean journal of hematology and infectious diseases.

[22]  J. Seward,et al.  Infiltrative cardiovascular diseases: cardiomyopathies that look alike. , 2010, Journal of the American College of Cardiology.

[23]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[24]  T. Therneau,et al.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Giampaolo Merlini,et al.  Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.

[26]  Panu Somervuo,et al.  How to make large self-organizing maps for nonvectorial data , 2002, Neural Networks.

[27]  Adrian E. Raftery,et al.  Model-Based Clustering, Discriminant Analysis, and Density Estimation , 2002 .

[28]  J. Kelly,et al.  Mechanisms of amyloidogenesis , 2000, Nature Structural Biology.

[29]  P. Dyck,et al.  The natural history of peripheral neuropathy in primary systemic amyloidosis , 1979, Annals of neurology.

[30]  J. Buxbaum,et al.  The genetics of the amyloidoses. , 2000, Annual review of medicine.